ERBB2 and breast cancer: The RIGHT Choice trial compared ribociclib + AI to investigator’s choice doublet chemotherapy (docetaxel + capecitabine; paclitaxel + gemcitabine; or capecitabine + vinorelbine) in pre/perimenopausal women with aggressive HR+/HER2– advanced breast cancer [62].